Home > Dermatology > IFPA WPPAC 2021 Highlights Podcast

IFPA WPPAC 2021 Highlights Podcast

Presented By
Dr Rachel Giles, Medicom
WPPAC 2021
  In this episode, Medicom’s correspondent covers 6 presentations held at the International Federation of Psoriasis Associations 6th World Psoriasis & Psoriatic Arthritis Conference (WPPAC) that took place 30 June to 3 July 2021. The topics discussed are: Based on the findings of the phase 3 POETYK PSO-1 and PSO-2 trials, deucravacitinib, a once-daily oral selective TYK2 inhibitor, has the potential to become an efficacious and well-tolerated treatment of choice for patients with moderate-to-severe plaque psoriasis. The first randomised, placebo-controlled trial in patients with generalised pustular psoriasis showed that IL-36 receptor inhibition with spesolimab resulted in rapid improvements in signs and symptoms of flares versus placebo, with sustained effects and a favourable benefit-risk profile Although treatment with immune checkpoint inhibitors was associated w...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on